Cancer Research · global
Making Drugs with Cancer Cells’ Carbon Monoxide: RIKEN Demonstrates Intracellular Synthesis of Anticancer Molecules
Producing drugs only after delivery to tumors could open a new path toward reducing systemic toxicity. A Japanese team used albumin to protect a palladium-containing complex and synthesize active molecules inside cultured cancer cells. However, a small amount of reaction also occurred in normal cells, and efficacy and safety remain to be tested in animals.
Could anticancer drugs cause less damage to healthy tissue if they were produced only after reaching a tumor? Katsunori Tanaka’s team at Japan’s RIKEN is attempting to use carbon monoxide produced by cancer cells themselves as a raw material for synthesizing anticancer molecules. The study demonstrated feasibility in cultured cells, but multiple hurdles remain before the approach could become a treatment for patients.
The study was published in *Nature Communications* on September 17, and RIKEN presented the findings on October 29. The team focused on the higher carbon monoxide production found in many cancer cells: besides being a metabolic product, this gas can participate in chemical reactions and serve as a structural building block for biologically active molecules. The researchers hope to exploit this difference to concentrate drug formation within cancer cells.
The challenge is that the palladium-containing complex that enables the reaction is readily deactivated by molecules such as glutathione after entering cells. The team therefore used a coumarin group as an “anchor” to position the palladium complex inside albumin’s hydrophobic binding pocket, providing protection. Cells then take up this assembly through endocytosis, giving it an opportunity to use endogenous carbon monoxide to synthesize phenanthridinone derivatives.
The first stage of experiments used a traceable product to confirm the reaction. After 48 hours of culture, four cell lines—liver, cervical, breast, and lung cancer—yielded 59 to 136 picomoles of product per million cells, compared with 15 picomoles in normal TIG3 fibroblasts. These data offer a more measured picture than the press release’s claim that the product was “not detected” in normal cells: conversion was lower in normal cells, but the reaction did not disappear entirely. Moreover, these values measure the traceable product and cannot be treated directly as evidence of cancer-killing effects.
Next, the researchers modified the design to allow the active molecules produced to detach from the carrier, and confirmed the formation of a cytotoxic phenanthridinone derivative inside liver cancer cells. The experiments also showed inhibition of cancer cell growth. However, the paper’s authors described the overall cytotoxicity as limited and characterized the findings as a proof of concept. The results do not yet establish whether the approach can achieve the level of cell killing needed for treatment.
Another key question is whether the drug might form prematurely in the blood. RIKEN stated that laboratory blood tests detected no drug formation. The researchers hypothesized that most carbon monoxide in blood is bound to hemoglobin and therefore cannot participate in the reaction. This provides a preliminary clue, but remains insufficient to establish the safety of the entire system in a living organism.
The next step is testing in animal models. This approach takes a disease-associated metabolite beyond its role as a recognition cue and turns it into a raw material for drug production, providing a concrete demonstration of intracellular chemical synthesis. Whether it can progress toward treatment still depends on delivery in living organisms, the efficiency of drug production, and whether a sufficient difference in reactivity can be maintained between cancer cells and normal tissues.